+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Prognostic value of pathological features of primary lesion in metastatic renal cell carcinoma treated with sorafenib



Prognostic value of pathological features of primary lesion in metastatic renal cell carcinoma treated with sorafenib



Future Oncology 12(15): 1783-1793



This study aimed to investigate whether the pathological features of primary lesions show additional prognostic value in patients with metastatic renal cell carcinoma who are treated with sorafenib. A consecutive cohort of 284 patients was included from Fudan University Shanghai Cancer Center between 2007 and 2013. The association between survival and pathological features of primary tumors was assessed using the Cox proportional hazards model. The incremental value of prognostication was evaluated. We found that the pathological features of primary lesions provided added prognostic value over the Memorial Sloan-Kettering Cancer Center model in patients with metastatic renal cell carcinoma who were treated with sorafenib. Addition of a pathological score in the clinical setting could better identify patients at risk of poor survival.

(PDF emailed within 0-6 h: $19.90)

Accession: 058637926

Download citation: RISBibTeXText

PMID: 27174049

DOI: 10.2217/fon-2016-0030


Related references

Overall prognostic impact of C-reactive protein level in patients with metastatic renal cell carcinoma treated with sorafenib. Anti-Cancer Drugs 27(10): 1028-1032, 2017

Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines. Urologic Oncology 32(4): 488-495, 2015

Clinicopathological and prognostic factors for long-term survival in Chinese patients with metastatic renal cell carcinoma treated with sorafenib: a single-center retrospective study. Oncotarget 6(34): 36870-36883, 2017

Prognostic prediction in patients with metastatic renal cell carcinoma treated with sorafenib based on expression levels of potential molecular markers in radical nephrectomy specimens. Urologic Oncology 31(1): 42-50, 2013

A pathological comparison of primary and metastatic lesions as a prognostic indicator for renal cell carcinoma. Nihon Hinyokika Gakkai Zasshi. Japanese Journal of Urology 86(4): 870-877, 1995

Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortium. Clinical Genitourinary Cancer 11(3): 311-315, 2014

The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet. Oncology 16(3): 293-300, 2015

Nephrotic-range proteinuria in a patient with a renal allograft treated with sorafenib for metastatic renal-cell carcinoma. Clinical and Experimental Nephrology 13(4): 397-401, 2009

Response evaluation criteria in solid tumors response of the primary lesion in metastatic renal cell carcinomas treated with sunitinib: does the primary lesion have to be regarded as a target lesion?. Clinical Genitourinary Cancer 11(3): 276-282, 2014

Clinical observation of 21 cases of metastatic renal cell carcinoma treated with sorafenib. Zhonghua Zhong Liu Za Zhi 31(9): 714-715, 2010

Percutaneous biopsy of primary tumor in metastatic renal cell carcinoma to predict high risk pathological features: comparison with nephrectomy assessment. Journal of Urology 184(5): 1877-1881, 2010

Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Annals of Oncology 19(2): 265-268, 2007

Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib. Bmc Cancer 12: 231, 2012

MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenib. Ajr. American Journal of Roentgenology 200(1): 120-126, 2013

Prognostic factors in renal cell carcinoma patients treated with sorafenib: results from the Czech registry. Targeted Oncology 10(3): 385-392, 2016